Oral cyclophosphamide in recurrent ovarian cancer.

@article{Handolias2016OralCI,
  title={Oral cyclophosphamide in recurrent ovarian cancer.},
  author={Despina Handolias and Michael A. Quinn and Serene S Foo and Linda Rose Mileshkin and Peter T Grant and Gaelle Dutu and Danny Rischin},
  journal={Asia-Pacific journal of clinical oncology},
  year={2016},
  volume={12 1},
  pages={e154-60}
}
AIMS Cyclophosphamide was widely used as a single agent prior to the advent of platinum-based regimens for epithelial ovarian cancer, and, in combination with platinum, prior to the adoption of platinum and paclitaxel as standard first-line therapy. As cyclophosphamide currently has no defined role in ovarian cancer we aimed to assess its activity in women with recurrent disease. METHODS A retrospective review was conducted of patients from three centers in Melbourne, Australia who had… CONTINUE READING
3 Citations
28 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 28 references

A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors

  • G Giaccone, A Rajan, RJ Kelly
  • J Clin Oncol
  • 2012

Pharmacodynamic response in phase I combination study of ABT-888 and topotecan in adults with refractory solid tumors and lymphomas

  • JJ Ji, S Kummar, AP Chen
  • J Clin Oncol
  • 2010

Similar Papers

Loading similar papers…